Merck (MRK) Research & Development (2009 - 2026)
Merck (MRK) reported Research & Development of $12.6 billion for Q1 2026, up 247.75% year-over-year from $3.6 billion in Q1 2025, and up 8294.67% on a QoQ basis from $150.0 million in Q4 2025.
Merck (MRK) has 18 years of Research & Development data on file, last reported at $12.6 billion in Q1 2026.
- Quarterly Research & Development rose 247.75% year-over-year to $12.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.0 billion (up 19.68% YoY) and the FY2025 annual result came in at $15.8 billion, down 11.98% from the prior year.
- Research & Development rose to $12.6 billion in Q1 2026 per MRK's latest filing, from $150.0 million in the prior quarter.
- Across five years, Research & Development topped out at $13.3 billion in Q2 2023 and bottomed at $150.0 million in Q4 2025.
- The 5-year median for Research & Development is $4.0 billion (2025), against an average of $4.9 billion.
- The widest annual swing landed in 2023, when Research & Development surged 376.09%; it then slumped 96.73% in 2025.
- Tracing MRK's Research & Development over 5 years: stood at $3.8 billion in 2022, then jumped by 45.7% to $5.5 billion in 2023, then dropped by 16.65% to $4.6 billion in 2024, then tumbled by 96.73% to $150.0 million in 2025, then jumped by 8294.67% to $12.6 billion in 2026.
- Per Business Quant, the three latest MRK Research & Development figures stand at $12.6 billion (Q1 2026), $150.0 million (Q4 2025), and $4.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.59 Bn |
| Dec 31, 2025 | 150.00 Mn |
| Sep 30, 2025 | 4.23 Bn |
| Jun 30, 2025 | 4.05 Bn |
| Mar 31, 2025 | 3.62 Bn |
| Dec 31, 2024 | 4.58 Bn |
| Sep 30, 2024 | 5.86 Bn |
| Jun 30, 2024 | 3.50 Bn |
| Mar 31, 2024 | 3.99 Bn |
| Dec 31, 2023 | 5.50 Bn |
| Sep 30, 2023 | 3.31 Bn |
| Jun 30, 2023 | 13.32 Bn |
| Mar 31, 2023 | 4.28 Bn |
| Dec 31, 2022 | 3.78 Bn |
| Sep 30, 2022 | 4.40 Bn |
| Jun 30, 2022 | 2.80 Bn |
| Mar 31, 2022 | 2.58 Bn |
| Dec 31, 2021 | 3.07 Bn |
| Sep 30, 2021 | 2.45 Bn |
| Jun 30, 2021 | 4.32 Bn |
| Mar 31, 2021 | 2.41 Bn |
| Dec 31, 2020 | 5.79 Bn |
| Sep 30, 2020 | 622.00 Mn |
| Jun 30, 2020 | 2.09 Bn |
| Mar 31, 2020 | 2.21 Bn |
| Dec 31, 2019 | 2.40 Bn |
| Sep 30, 2019 | 3.20 Bn |
| Jun 30, 2019 | 2.19 Bn |
| Mar 31, 2019 | 1.93 Bn |
| Dec 31, 2018 | 2.21 Bn |
| Sep 30, 2018 | 2.07 Bn |
| Jun 30, 2018 | 2.27 Bn |
| Mar 31, 2018 | 1.40 Bn |
| Dec 31, 2017 | 2.32 Bn |
| Sep 30, 2017 | 4.41 Bn |
| Jun 30, 2017 | 1.78 Bn |
| Mar 31, 2017 | 1.83 Bn |
| Dec 31, 2016 | 4.79 Bn |
| Sep 30, 2016 | 1.66 Bn |
| Jun 30, 2016 | 2.15 Bn |
| Mar 31, 2016 | 1.66 Bn |
| Dec 31, 2015 | 1.80 Bn |
| Sep 30, 2015 | 1.50 Bn |
| Jun 30, 2015 | 1.67 Bn |
| Mar 31, 2015 | 1.74 Bn |
| Dec 31, 2014 | 2.28 Bn |
| Sep 30, 2014 | 1.66 Bn |
| Jun 30, 2014 | 1.66 Bn |
| Mar 31, 2014 | 1.57 Bn |
| Dec 31, 2013 | 1.84 Bn |
| Sep 30, 2013 | 1.66 Bn |
| Jun 30, 2013 | 2.10 Bn |
| Mar 31, 2013 | 1.91 Bn |
| Dec 31, 2012 | 2.22 Bn |
| Sep 30, 2012 | 1.92 Bn |
| Jun 30, 2012 | 2.17 Bn |
| Mar 31, 2012 | 1.86 Bn |
| Dec 31, 2011 | 2.42 Bn |
| Sep 30, 2011 | 1.95 Bn |
| Jun 30, 2011 | 1.94 Bn |
| Mar 31, 2011 | 2.16 Bn |
| Dec 31, 2010 | 4.56 Bn |
| Sep 30, 2010 | 2.32 Bn |
| Jun 30, 2010 | 2.18 Bn |
| Mar 31, 2010 | 2.05 Bn |
| Dec 31, 2009 | 1.97 Bn |
| Sep 30, 2009 | 1.25 Bn |
| Jun 30, 2009 | 1.40 Bn |
| Mar 31, 2009 | 1.22 Bn |